TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07325279: Nalmefene Implant in Healthy Subjects

Sponsor: ReacX Pharmaceuticals, Inc. · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 24 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$5,802,032

Rescue Site Savings

+$3,837,920

Unlock Full NCT07325279 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07325279 Rescue Dossier →